Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours

British Journal of Cancer

Volumn 102, Issue 7, 2010, Pages 1106-1112

  Turner, N C ^a   Strauss, S J ^a   Sarker, D ^a   Gillmore, R ^a   Kirkwood, A ^b   Hackshaw, A ^b   Papadopoulou, A ^c   Bell, J ^c   Kayani, I ^d   Toumpanakis, C ^c   Grillo, F ^e   Mayer, A ^a   Hochhauser, D ^a   Begent, R H ^a   Caplin, M E ^c   Meyer, T ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chemotherapy; Ki 67; Mitotic index; NETs

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CHROMOGRANIN A; CISPLATIN; FLUOROURACIL; KI 67 ANTIGEN; OCTREOTIDE; STREPTOZOCIN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL FEATURE; DIARRHEA; DRUG SUBSTITUTION; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STOMATITIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; STREPTOZOCIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950367451     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605618     Document Type: Article

References (22)

1. Ansell SM, Pitot HC, Burch PA, Kvols LK, Mahoney MR, Rubin J (2001) A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 91(8): 1543-1548
2. Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B, Costanzi JH (1987) A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60(12): 2891-2895
3. Cheng PN, Saltz LB (1999) Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 86(6): 944-948
4. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13(10): 2986-2991
5. Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass Jr HO (1984) Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2(11): 1255-1259
6. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg K (1990) Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumours. Cancer 65(9): 1883-1890
7. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, Eriksson BK (2001) Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92(5): 1101-1107
8. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC (2004) Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22(23): 4762-4771
9. Kulke MH, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS (2004) A phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 101(5): 934-939
10. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendo-crine tumors. J Clin Oncol 24(3): 401-406 (Pubitemid 46630459) (Pubitemid 46630459)
11. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufie P, Aparicio T, Aparicio T, Lasser P, Elias D, Duvillard P, Schlumberger M, Rougier P (1999) Treatment of poorly differentiated neuroendocrine tumours with etopo-side and cisplatin. Br J Cancer 81(8): 1351-1355
12. Moertel CG, Hanley JA, Johnson LA (1980) Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 303(21): 1189-1194
13. Moertel CG, Kvols LK, O'Connell MJ, Rubin J (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68(2): 227-232
14. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D (1992) Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326(8): 519-523
15. Pape UF, Berndt U, Mueller-Nordhorn J, Boehmig M, Roll S, Koch M, Willich S, Wiedenmann B (2008a) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4): 1083-1097
16. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, Koch M, Rocken C, Rindi G, Wiedenmann B (2008b) Prognostic relevance of a novel TNM classification system for upper gastroentero-pancreatic neuroendocrine tumors. Cancer 113(2): 256-265
17. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4): 395-401
18. Shah T, Srirajaskanthan R, Bhogal M, Toubanakis C, Meyer T, Noonan A, Witney-Smith C, Amin T, Bhogal P, Sivathasan N, Warner B, Hochhauser D, Caplin ME (2008) Alpha-fetoprotein and human chorionic gonado-trophin-beta as prognostic markers in neuroendocrine tumour patients. Br J Cancer 99(1): 72-77
19. Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG (2005) Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23(22): 4897-4904
20. Toumpanakis C, Meyer T, Caplin ME (2007) Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 21(1): 131-144
21. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J (2007) Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 14(2): 221-232
22. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB (2008) One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendo-crine tumors in 35825 cases in the United States. J Clin Oncol 26(18): 3063-3072